Genmab — Marts 2019
-
Sjældent set med samtlige aktier i porteføljerne.
-
Kn en enkelt laks svømmer i overfladen.
-
Den er ikke blevet handlet.
-
Mine laks er kun blegrøde. De er altid gode, når der generelle fald i markederne. Genmab klarer sig også ok med A/B som største køber igen igen.
-
Nordea på købersiden O.o
-
"Fimsede"!!!!!!
-
Så er vi snart i + igen..:-)
-
Vi ER i plus.
-
så vendte fornuften tilbage
-
"Daratumumab appears to be the “gift that keeps on giving” to the myeloma community. " http://www.ascopost.com/issues/march-25-2019/benefit-of-adding-daratumumab-to-initial-therapy-in-multiple-myeloma/
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind